[
  {
    "ts": "2025-11-21T07:14:06+00:00",
    "headline": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
    "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
    "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "87d20a7c-cacb-3e91-a883-5b1481c14be5",
      "content": {
        "id": "87d20a7c-cacb-3e91-a883-5b1481c14be5",
        "contentType": "STORY",
        "title": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
        "description": "",
        "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
        "pubDate": "2025-11-21T07:14:06Z",
        "displayTime": "2025-11-21T07:14:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T13:00:00+00:00",
    "headline": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
    "summary": "The drugmaker may not continue to lag the market for much longer.",
    "url": "https://www.fool.com/investing/2025/11/21/this-7-yielding-dividend-stock-is-about-to-enter/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "94a9de7a-4ce4-3f35-8d8a-81fa5c455e4d",
      "content": {
        "id": "94a9de7a-4ce4-3f35-8d8a-81fa5c455e4d",
        "contentType": "STORY",
        "title": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
        "description": "",
        "summary": "The drugmaker may not continue to lag the market for much longer.",
        "pubDate": "2025-11-21T13:00:00Z",
        "displayTime": "2025-11-21T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor and patient in a hospital room.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qh7xsLg1i0wtlmLPaJEwCQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OqAeJoWOLZr5hSBNbRkgEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/21/this-7-yielding-dividend-stock-is-about-to-enter/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/7-yielding-dividend-stock-enter-130000462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T12:41:00+00:00",
    "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
    "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
    "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "315ef055-ab2e-322b-befd-e292f7e8f8f0",
      "content": {
        "id": "315ef055-ab2e-322b-befd-e292f7e8f8f0",
        "contentType": "STORY",
        "title": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
        "description": "",
        "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
        "pubDate": "2025-11-21T12:41:00Z",
        "displayTime": "2025-11-21T12:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]